Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs. For more information, visit www.ascidian-tx.com.
Company Details
- Employees
- 47
- Founded
- -
- Address
- 80 Guest St, Boston,massachusetts 02135,united States
- Industry
- Biotechnology
- Website
- http://www.ascidian-tx.com
- Keywords
- gene therapy, biotechnology, RNA therapeutics.
- HQ
- Boston, Massachusetts
Ascidian Therapeutics Questions
Ascidian Therapeutics's website is http://www.ascidian-tx.com
Ascidian Therapeutics's LinkedIn profile is https://www.linkedin.com/company/ascidian-therapeutics
Ascidian Therapeutics has
47 employees.
View email and phone details for 47
employees at Ascidian Therapeutics.
Ascidian Therapeutics's industry is
Biotechnology
Ascidian Therapeutics's top competitors are
Abdera Therapeutics,
Profound Therapeutics,
Excision Biotherapeutics,
Belharra Therapeutics,
Seaport Therapeutics,
Tessera Therapeutics,
Capstan Therapeutics,
Xaira Therapeutics,
Sarepta Therapeutics,
Rapport Therapeutics.
Ascidian Therapeutics's categories are Biotechnology
Ascidian Therapeutics's founding year is 2020
